Department of Surgery, VUmc Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
World J Surg. 2013 Jun;37(6):1340-7. doi: 10.1007/s00268-013-1997-6.
Patients with colorectal liver metastases (CRLM) who are ineligible for curative surgery are potential candidates for radiofrequency ablation (RFA). Although RFA has emerged as a well accepted and documented treatment modality, there are still some reservations because of initially high rates of local site recurrences (LSR). The aim of the present study was to evaluate LSR levels following RFA treatment, with a specific focus on re-treatment and survival.
All patients ineligible for curative resection of CRLM and undergoing RFA alone or in combination with resection were prospectively included from July 2000 to December 2010 and retrospectively analyzed. Patients with untreatable extrahepatic disease were excluded. FDG PET-CT was conducted at 3-6 month intervals after RFA. Patients with LSR were evaluated for re-treatment.
A total of 132 patients were treated with RFA, which was combined with resection in 64 patients. A total of 290 lesions were ablated, with a mean number of 2.19 per patient and a mean size of 2.2 cm. Median survival was 41 months, with a 3- and 5-year survival of, respectively, 60 and 30.8 %. Following initial RFA, 39 patients developed an LSR in 40 ablated lesions, and local recurrence was strongly related to lesion size. Re-treatment could be performed in 26/39 patients, of whom eight remained disease-free.
Radiofrequency ablation can be applied to CRLM of less than 3 cm with curative intent. In the absence of extensive intrahepatic or extrahepatic disease, renewed treatment of local recurrences should be considered and is often successful.
不适合进行根治性手术的结直肠癌肝转移(CRLM)患者是射频消融(RFA)的潜在候选者。尽管 RFA 已成为一种公认且有记录的治疗方式,但由于初始局部复发(LSR)率较高,仍存在一些保留意见。本研究旨在评估 RFA 治疗后 LSR 水平,重点关注再治疗和生存。
所有不适合根治性切除 CRLM 且单独或联合切除行 RFA 的患者均于 2000 年 7 月至 2010 年 12 月前瞻性纳入并进行回顾性分析。排除不可治疗的肝外疾病患者。RFA 后 3-6 个月行 FDG PET-CT。对 LSR 患者进行再治疗评估。
共 132 例患者接受 RFA 治疗,其中 64 例联合切除。共消融 290 个病灶,平均每个患者 2.19 个,平均大小为 2.2cm。中位生存时间为 41 个月,3 年和 5 年生存率分别为 60%和 30.8%。初始 RFA 后,39 例患者的 40 个消融病灶出现 LSR,局部复发与病灶大小密切相关。26/39 例患者可进行再治疗,其中 8 例仍无疾病。
RFA 可用于小于 3cm 的 CRLM 进行根治性治疗。在无广泛的肝内或肝外疾病的情况下,应考虑对局部复发进行重新治疗,且通常是成功的。